Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies. / Jansåker, Filip; Bollestad, Marianne; Vik, Ingvild; Lindbæk, Morten; Bjerrum, Lars; Frimodt-Møller, Niels; Knudsen, Jenny Dahl.

In: Antibiotics, Vol. 8, No. 2, 57, 2019.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Jansåker, F, Bollestad, M, Vik, I, Lindbæk, M, Bjerrum, L, Frimodt-Møller, N & Knudsen, JD 2019, 'Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies', Antibiotics, vol. 8, no. 2, 57. https://doi.org/10.3390/antibiotics8020057

APA

Jansåker, F., Bollestad, M., Vik, I., Lindbæk, M., Bjerrum, L., Frimodt-Møller, N., & Knudsen, J. D. (2019). Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies. Antibiotics, 8(2), [57]. https://doi.org/10.3390/antibiotics8020057

Vancouver

Jansåker F, Bollestad M, Vik I, Lindbæk M, Bjerrum L, Frimodt-Møller N et al. Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies. Antibiotics. 2019;8(2). 57. https://doi.org/10.3390/antibiotics8020057

Author

Jansåker, Filip ; Bollestad, Marianne ; Vik, Ingvild ; Lindbæk, Morten ; Bjerrum, Lars ; Frimodt-Møller, Niels ; Knudsen, Jenny Dahl. / Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies. In: Antibiotics. 2019 ; Vol. 8, No. 2.

Bibtex

@article{fceab561c9ac49ec8464668a007d02e8,
title = "Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies",
abstract = "Objectives: To investigate pivmecillinam´s efficacy in uncomplicated lower urinary tract infection (UTI) caused by Staphylococcus saprophyticus-considered non-susceptible to mecillinam. Methods: Participants with confirmed UTIs caused by S. saprophyticus from four randomized controlled trials, where pivmecillinam was empirically given to females with symptoms of UTIs. The primary outcome was defined as a cumulative clinical effect-symptom resolution during the first eight days of therapy, without a recurrence of UTI symptoms in the long-term follow-up (approximately four weeks). Secondary outcomes included the bacteriological effect-elimination of the causative agent, with or without new uropathogenic bacteria present in the first control urine sample. Significant bacteriuria was defined as ≥103 bacteria/mL. The antibiotic susceptibility testing was done by disc diffusion methodology, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Results: Seventy-four females (18-55 years) were empirically treated with pivmecillinam for UTIs caused by S. saphrophyticus (mean age 25 years; standard deviation (SD) 5.8). The cumulative clinical effect was 53/74 (72{\%}), and the bacteriological effect was 51/59 (86{\%}). Conclusion: Pivmecillinam showed a high clinical and bacteriological effect in UTIs caused by S. saprophyticus in these four clinical trials. The characterization of non-susceptibility for mecillinam regarding the treatment of UTIs caused by this common pathogen may need to be revised.",
author = "Filip Jans{\aa}ker and Marianne Bollestad and Ingvild Vik and Morten Lindb{\ae}k and Lars Bjerrum and Niels Frimodt-M{\o}ller and Knudsen, {Jenny Dahl}",
year = "2019",
doi = "10.3390/antibiotics8020057",
language = "English",
volume = "8",
journal = "Antibiotics",
issn = "2079-6382",
publisher = "M D P I AG",
number = "2",

}

RIS

TY - JOUR

T1 - Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies

AU - Jansåker, Filip

AU - Bollestad, Marianne

AU - Vik, Ingvild

AU - Lindbæk, Morten

AU - Bjerrum, Lars

AU - Frimodt-Møller, Niels

AU - Knudsen, Jenny Dahl

PY - 2019

Y1 - 2019

N2 - Objectives: To investigate pivmecillinam´s efficacy in uncomplicated lower urinary tract infection (UTI) caused by Staphylococcus saprophyticus-considered non-susceptible to mecillinam. Methods: Participants with confirmed UTIs caused by S. saprophyticus from four randomized controlled trials, where pivmecillinam was empirically given to females with symptoms of UTIs. The primary outcome was defined as a cumulative clinical effect-symptom resolution during the first eight days of therapy, without a recurrence of UTI symptoms in the long-term follow-up (approximately four weeks). Secondary outcomes included the bacteriological effect-elimination of the causative agent, with or without new uropathogenic bacteria present in the first control urine sample. Significant bacteriuria was defined as ≥103 bacteria/mL. The antibiotic susceptibility testing was done by disc diffusion methodology, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Results: Seventy-four females (18-55 years) were empirically treated with pivmecillinam for UTIs caused by S. saphrophyticus (mean age 25 years; standard deviation (SD) 5.8). The cumulative clinical effect was 53/74 (72%), and the bacteriological effect was 51/59 (86%). Conclusion: Pivmecillinam showed a high clinical and bacteriological effect in UTIs caused by S. saprophyticus in these four clinical trials. The characterization of non-susceptibility for mecillinam regarding the treatment of UTIs caused by this common pathogen may need to be revised.

AB - Objectives: To investigate pivmecillinam´s efficacy in uncomplicated lower urinary tract infection (UTI) caused by Staphylococcus saprophyticus-considered non-susceptible to mecillinam. Methods: Participants with confirmed UTIs caused by S. saprophyticus from four randomized controlled trials, where pivmecillinam was empirically given to females with symptoms of UTIs. The primary outcome was defined as a cumulative clinical effect-symptom resolution during the first eight days of therapy, without a recurrence of UTI symptoms in the long-term follow-up (approximately four weeks). Secondary outcomes included the bacteriological effect-elimination of the causative agent, with or without new uropathogenic bacteria present in the first control urine sample. Significant bacteriuria was defined as ≥103 bacteria/mL. The antibiotic susceptibility testing was done by disc diffusion methodology, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Results: Seventy-four females (18-55 years) were empirically treated with pivmecillinam for UTIs caused by S. saphrophyticus (mean age 25 years; standard deviation (SD) 5.8). The cumulative clinical effect was 53/74 (72%), and the bacteriological effect was 51/59 (86%). Conclusion: Pivmecillinam showed a high clinical and bacteriological effect in UTIs caused by S. saprophyticus in these four clinical trials. The characterization of non-susceptibility for mecillinam regarding the treatment of UTIs caused by this common pathogen may need to be revised.

U2 - 10.3390/antibiotics8020057

DO - 10.3390/antibiotics8020057

M3 - Journal article

VL - 8

JO - Antibiotics

JF - Antibiotics

SN - 2079-6382

IS - 2

M1 - 57

ER -

ID: 218395225